Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

HPV vaccine shows promise for girls on Immune-Suppressing drugs

NCT ID NCT01687192

Vaccine Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether the HPV vaccine works in girls aged 9 to 17 who are taking medicines that weaken their immune system, such as after an organ transplant or for diseases like lupus. The goal was to see if their bodies produce enough antibodies to protect against HPV. The results help doctors understand if these girls can get the same protection from the vaccine as healthy girls.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 37 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2012

Finished

Oct 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

9 to 18 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female gender * Age ≥ 9 years and \< 18 years * Weight ≥ 25 kg * Solid organ transplantation: kidney, liver, heart, lung, intestinal or combined transplant; or systemic lupus erythematosus or other systemic immune disease * Transplantation or diagnosis of lupus or diagnosis of systemic immune disease since more than 6 months * Immunosuppressant treatment by anti-metabolites or calcineurin inhibitors, with or without associated corticosteroids * Minimum required period of 3 months considered as stable after transplantation or without relapse of lupus according to physician evaluation * In case of sexual activity (assessed by auto-declaration): onset less than one year before inclusion * Written informed consent signed by the investigator and the legal representatives of the patient, and assent by the patient Exclusion Criteria: * Male gender * Pregnancy * Age \< 9 years or ≥ 18 years * Previous HPV vaccination * Immunosuppressive treatment by anti-TNF (adalimumab, etanercept, infliximab) or monoclonal antibodies (rituximab, anakinra, abatacept) during the last 3 months * Active malignancy * Active opportunistic infection * HIV infection * Concurrent clinical trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Systemic immune disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

HIV Seropositivity immune system disorder systemic lupus erythematosus human papilloma virus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Systemic immune disease Systemic lupus erythematosus Transplantation

Contacts and locations

Locations

  • AP-HP, Hôpital Armand Trousseau

    Paris, 75571, France

  • AP-HP, Hôpital Necker-Enfants

    Paris, 75743, France

  • AP-HP, Hôpital Robert Debré

    Paris, 75019, France

  • CHU de Bordeaux, Hôpital Pellegrin-Enfants

    Bordeaux, 33076, France

  • CHU de Lille, Hôpital Jeanne de Flandres

    Lille, 59037, France

  • CHU de Montpellier, Hôpital Arnaud de Villeneuve

    Montpellier, 34295, France

  • CHU de Nantes, Hôpital Mère-Enfants

    Nantes, 44093, France

  • CHU de Toulouse, Hôpital des Enfants

    Toulouse, 31059, France

  • HCLyon, Hôpital Femme-mère-enfant

    Bron, 69677, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.